
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences is a clinical-stage biotechnology company with a unique approach to treating neurodegenerative diseases such as Alzheimer's and ALS. Their lead product candidate, PMN310, targets toxic oligomers of amyloid-beta, known to be the primary drivers of neurotoxicity in Alzheimer's. With a differentiated safety profile and strong early data, ProMIS has the potential to become a major player in this high-demand market. Additionally, the company's Phase III design and strategic considerations, as well as the potential for partnerships and strategic interest, provide further upside potential.
Bears say
ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapies for neurodegenerative diseases like AD, ALS, and MSA. While the company's innovative platform shows promise, there are significant risks involved in its development of PMN310, including competition from established players, the need for significant capital for P2b/3 programs, and potential difficulty in interpreting interim results. Additionally, the company's financials show a net loss of $11.7 million in Q2 2026, and there may be challenges in achieving statistical significance on cognitive endpoints with the upcoming 1Q27 readout. These factors contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares